Mylan sued by Daiichi Sankyo over Azor patent
US generics major Mylan says that its majority-owned subsidiary, Matrix Laboratories, is being sued by Japan's Daiichi Sankyo in connection with amlodipine besylate/olmesartan medoxomil tablets, 5mg/20mg, 10mg/20mg, 5mg/40mg and 10mg/40mg, the generic version of the latter's Azor tablets.
Mylan believes that Matrix is the first company to file a substantially complete Abbreviated New Drug Application containing a Paragraph IV certification for the product. Matrix filed with the Food and Drug Administration in early 2008.
Daiichi Sankyo filed a law suit on June 3 in the US District Court for the District of New Jersey alleging infringement of the sole patent relating to Azor, which is listed in the "Orange Book" as US Patent No 5,616,599.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze